Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 89
- 试验地点
- 4
- 主要终点
- Objective response rate (ORR) (ARID1A cohort)
研究概览
简要总结
This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma (RCC), urothelial carcinoma, all pancreatic cancers, endometrial cancer, and other solid tumors excluding clear cell ovarian cancer that have spread to nearby tissue or lymph nodes or other parts of the body. ATR kinase inhibitor AZD6738 and olaparib or durvalumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not known if giving ATR kinase inhibitor AZD6738 with or without olaparib or durvalumab may work better in treating participants with solid tumors.
详细描述
PRIMARY OBJECTIVES:
I. To assess objective response rate (ORR) of ceralasertib monotherapy and ceralasertib + olaparib by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria (ARID1A Cohort). II. To assess the composite response rate (objective response and/or PSA50 response) of ceralasertib monotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) (N = 5-10) harboring pathogenic ATM mutations and/or loss of ATM expression by Immunohistochemistry (IHC) (ATM Cohort).
III. To assess objective response rate of ceralasertib monotherapy in patients with other advanced solid tumor malignancies harboring pathogenic ATM mutations and/or loss of ATM expression by IHC (ATM Cohort).
IV. To assess the objective response rate (ORR) of ceralasertib in combination with durvalumab by RECIST 1.1 criteria (Endometrial Cohort)
SECONDARY OBJECTIVES:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must provide written informed consent prior to performance of study-specific procedures or assessments.
- •ARID1A Subgroup (N = 39):
- •Histologically confirmed locally advanced or metastatic solid tumor malignancy with progression on at least one prior systemic therapy, including one of the following tumor types:
- •Renal cell carcinoma with predominant clear cell histology (Cohort A)
- •Urothelial carcinoma (Cohort B)
- •All pancreatic cancers (Cohort C)
- •Other solid tumors excluding clear cell ovarian cancer and endometrial cancer (Cohort D)
- •Endometrial and ovarian cancer (Cohort E)
- •Formalin-fixed paraffin embedded tumor tissue evaluable for BAF250a expression by ARID1A immunohistochemistry. Primary or metastatic tumor tissue is permissible. Patients without evaluable archival tissue may undergo optional tumor biopsy during Screening if other eligibility criteria have been met
- •Measurable disease by RECIST 1.1
- •ATM Loss Subgroup (N = 20):
- •Histologically confirmed locally advanced or metastatic solid tumor malignancy with progression on at least one prior systemic therapy, including one of the following tumor types:
- •Metastatic castration resistant prostate cancer (N = 10).
- •Patients may have evaluable or measurable disease by RECIST 1.1 criteria.
- •Prior treatment with at least one androgen signaling inhibitor (e.g. abiraterone, enzalutamide, apalutamide, darolutamide).
- •Patients will be required to maintain castrate levels of testosterone during study treatment with use of Luteinizing hormone-releasing hormone (LHRH) analog (except for patients with history of bilateral orchiectomy).
- •Progression by PCWG3 criteria at study entry
- •All other solid tumor malignancies (N = 10). Patients are required to have measurable soft tissue disease by RECIST 1.1 criteria.
- •Archival tumor tissue evaluable for ATM expression by immunohistochemistry (IHC)
- •Evidence of ATM loss by either pathogenic ATM mutation in Chemiluminescent immunoassay (CLIA)-approved assay and/or loss of ATM expression by IHC (Ventana Ab). An interim analysis will be performed after 10 patients are enrolled. If less than 50% of tumors have absence of ATM expression by IHC, subsequent enrollment of the remaining 10 patients will be required to have evidence of both ATM mutation and loss of ATM expression (< 5% of tumor cells expressing ATM) using CLIA-certified IHC test (Ventana).
- •Endometrial Cancer Cohort (N = 30):
- •Histologically confirmed endometrial cancer
- •o A minimum of 15 patients must have the presence of pathogenic ARID1A alteration on CLIA-approved next-generation sequencing panel without evidence of microsatellite instability defined by next-generation sequencing and/or presence of intact mismatch repair proteins by immunohistochemistry.
- •Measurable disease by RECIST 1.
- •Availability of archival tumor tissue for retrospective testing of BAF250a expression by IHC.
- •Has received at least one prior line of systemic therapy for the treatment of locally advanced or metastatic disease, including progression on at least one prior line of therapy containing an immune checkpoint inhibitor that was administered for a minimum duration of 6 weeks
- •Must not have experienced a toxicity that led to permanent discontinuation of prior immune checkpoint inhibitor.
- •All adverse events (AE) while receiving prior immune checkpoint inhibitor must have completely resolved or resolved to baseline prior to screening for this study.
- •Must not have experienced a >= Grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immune checkpoint inhibitor. NOTE: Patients with endocrine AE of <=Grade 2 are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic.
- •Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > 10 mg prednisone or equivalent per day.
- •Body weight >30 kg
- •No active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
- •Patients with vitiligo or alopecia.
- •Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.
- •Any chronic skin condition that does not require systemic therapy.
- •Patients without active disease in the last 5 years may be included but only after consultation with the Principal Investigator.
- •Patients with celiac disease controlled by diet alone.
- •Evidence of clinical or radiographic progression prior to study entry (except metastatic castrate-resistant prostate cancer (mCRPC) cohort which requires progression by PCWG3 criteria).
- •Age >= 18 years at time of signing informed consent form.
- •Resolution of all prior treatment-related toxicities to grade 1 severity or lower (except alopecia).
- •Patients must be at least 3 weeks or 5 half-lives (whichever is shorter) from last standard or experimental non-cytotoxic therapy prior to first dose of protocol therapy. Patients must be > 21 days from last dose of cytotoxic chemotherapy prior to C1D
- •The minimum wash-out period for immunotherapy is 42 days prior to C1D1 with the following exception for the Endometrial cohort: Note: Washout from prior immunotherapy is >=21 days to C1D1 for the Endometrial cohort.
- •Radiation therapy must be completed > 7 days prior to course 1 day 1 (C1D1) or > 28 days prior to C1D1 for patients receiving radiation to more than 30% of bone marrow.
- •Adequate organ function as defined by:
- •Hemoglobin (Hgb) >= 9.0 g/dL in the absence of transfusion within 14 days prior to screening laboratory assessment.
- •Platelets (Plt) count > 100,000 x 10^9/L.
- •Absolute neutrophil count > 1.5 x 10^9/L.
- •Estimated glomerular filtration rate (GFR) >= 45 ml/min based on Cockcroft-Gault equation or 24 hour urine collection.
- •Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) (< 5x ULN in patients with known liver metastases).
- •Total bilirubin < 1.5 x ULN (direct bilirubin < 1.5 x ULN in patients with known Gilbert's disease or UGT1A1 homozygote).
- 另有 8 项未显示
排除标准
- •History of secondary malignancy requiring treatment within 1 year prior to screening, with the exception of carcinoma in situ of the cervix, non-melanoma skin carcinoma, low/intermediate risk localized prostate cancer (=< Gleason 7, =< T2N0M0, and prostate-specific antigen (PSA) =< 20 ng/mL at diagnosis) (not applicable for prostate cancer cohort), ductal carcinoma in situ, Stage I uterine cancer, and non-muscle invasive urothelial carcinoma
- •Patients receiving, or having received within 14 days of C1D1, corticosteroids at a dose > 10 mg/day of prednisone (or equivalent).
- •Patients with myelodysplastic syndrome or features suggestive of myelodysplastic syndrome.
- •Prior treatment with ATR inhibitor
- •Major surgical procedures < 28 days prior to C1D
- •Patients must have recovered to grade =< 1 for any adverse events related to the surgical procedure.
- •Untreated central nervous system (CNS) metastases. Patients with previously treated central nervous system (CNS) metastases are eligible if:
- •No requirement for corticosteroids at study entry
- •Radiographically and clinically stable for at least 4 weeks prior to study entry
- •No evidence of intra-tumoral hemorrhage
- •No evidence of current or prior leptomeningeal disease.
- •Clinically significant gastrointestinal abnormalities that may increase the risk of decreased absorption of medications, including:
- •Inability to swallow oral medications
- •Active peptic ulcer disease
- •Known intra-luminal metastatic lesions
- •History of abdominal fistula or bowel perforation
- •History of bowel obstruction within 6 months prior to study entry
- •Known malabsorption syndrome
- •Significant resection of the small bowel.
- •Fridericia's QT correction formula (QTcF) > 470 ms (females) or > 450 ms (males) on screening electrocardiography (ECG), or immediate family history of congenital long QT syndrome or sudden cardiac death at age less than
- •History of any one or more of the following cardiovascular conditions within the past 6 months:
- •Myocardial infarction
- •Unstable angina
- •Transient ischemic attack or cerebrovascular accident
- •Uncontrolled arrhythmia. Rate controlled atrial fibrillation/flutter is not an exclusion for the study.
- •Class III or IV congestive heart failure or documented left ventricle (LV) ejection fraction of < 50% (screening not required).
- •Uncontrolled hypertension as defined by systolic blood pressure > 160 mm Hg and/or diastolic blood pressure > 100 mm Hg. Adjustment of anti-hypertensive regimen and re-screening is permitted.
- •Relative hypotension with resting blood pressure of less than 90 mm Hg systolic and less than 60 mm Hg diastolic or symptomatic orthostatic hypotension.
- •Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with patient's safety or adherence to study procedures including uncontrolled infection requiring parenteral antibiotics.
- •Concomitant use of strong cytochrome P450, family 3, subfamily A (CYP3A4) inhibitors, strong CYP3A4 inducers, CYP3A4 substrates with narrow therapeutic index, or CYP2B6 substrates with narrow therapeutic index within 21 days or 5 half-lives, whichever is shorter, prior to C1D1 of study treatment
- •The use of herbal supplements or 'folk remedies' (and medications and foods that significantly modulate CYP3A activity) should be discouraged. If deemed necessary, such products may be administered with caution and the reason for use documented in the case report form (CRF).
- •A known hypersensitivity to olaparib, ceralasertib, durvalumab (as applicable to the study drugs the patient is receiving), or any excipient of the product or any contraindication to the combination anti-cancer agent as per local prescribing information.
- •A known chronic active hepatitis B or C (defined by positive viral load; screening not required).
- •Immunocompromised patients, including those serologically positive for human immunodeficiency virus (HIV), those receiving chronic immunosuppression, or those with prior allogeneic or cord blood transplantation.
- •History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
- •Presence of prolonged severe cytopenia (≥ Grade 3 for ≥ 2 weeks) prior to enrolment.
研究组 & 干预措施
Arm III (Ceralasertib, Durvalumab)
In combination with durvalumab, ceralasertib will be given at a continuous daily dose of 240 mg BID days 1-7 of a 28-day dosing schedule. Durvalumab will be given at a flat dose of 1500 mg IV on day 8 of a 28-day cycle for participants with histologically confirmed endometrial cancers. Participants treated with the combination of ceralasertib plus durvalumab may continue treatment beyond first radiographic progression until the occurrence of either confirmed radiographic progression or clinical progression, whichever occurs first.
干预措施: Durvalumab (Drug)
Arm I (Ceralasertib Monotherapy)
As monotherapy ceralasertib will be given at a starting dose of 160 mg two times per day (BID), on days 1-14 of a 28-day cycle for participants who are BAF250a negative or show an ATM-Mutation by CLIA assay. Treatment will continue until disease progression, unacceptable toxicity, or participant withdrawal from study, whichever occurs first.
干预措施: Ceralasertib (Drug)
Arm II (Ceralasertib, Olaparib)
In combination with olaparib, ceralasertib will be given at a continuous daily dose of 160 mg daily days 1-7 in each 28-day cycle. Olaparib will be given at a starting dose of 300 mg twice daily days 1-28 of a 28-day cycle for participants who are BAF250a positive. Treatment will continue until disease progression, unacceptable toxicity, or participant withdrawal from study, whichever occurs first.
干预措施: Ceralasertib (Drug)
Arm III (Ceralasertib, Durvalumab)
In combination with durvalumab, ceralasertib will be given at a continuous daily dose of 240 mg BID days 1-7 of a 28-day dosing schedule. Durvalumab will be given at a flat dose of 1500 mg IV on day 8 of a 28-day cycle for participants with histologically confirmed endometrial cancers. Participants treated with the combination of ceralasertib plus durvalumab may continue treatment beyond first radiographic progression until the occurrence of either confirmed radiographic progression or clinical progression, whichever occurs first.
干预措施: Ceralasertib (Drug)
Arm II (Ceralasertib, Olaparib)
In combination with olaparib, ceralasertib will be given at a continuous daily dose of 160 mg daily days 1-7 in each 28-day cycle. Olaparib will be given at a starting dose of 300 mg twice daily days 1-28 of a 28-day cycle for participants who are BAF250a positive. Treatment will continue until disease progression, unacceptable toxicity, or participant withdrawal from study, whichever occurs first.
干预措施: Olaparib (Drug)
结局指标
主要结局
Objective response rate (ORR) (ARID1A cohort)
时间窗: Up to 3 years
On overall response will be reported as a percentage of participants with a complete response (CR) or partial response (PR) as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Objective response rate (ORR) for endometrial cohort
时间窗: Up to 3 years
ORR for participants with endometrial cancers will be measured using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and Will be based on one-sided exact binomial test comparison of the observed ORR in evaluable patients to the null-hypothesized value of 5%, using the 5% significance level.
Composite Prostate Cancer Patient Response Rate (prostate cancer only)
时间窗: Up to 3 years
In prostate cancer patients only: To determine the 50% decline in prostate-specific antigen (PSA50) response rate Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria or objective response by RECIST 1.1
Objective response rate (ORR) for other solid tumors
时间窗: Up to 3 years
ORR for participants with other solid tumors will be measured using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and Will be based on one-sided exact binomial test comparison of the observed ORR in evaluable patients to the null-hypothesized value of 5%, using the 5% significance level.
次要结局
- Median duration of response (DOR) by disease group(Up to 3 years)
- Median duration of response (DOR) by treatment regimen(Up to 3 years)
- Median progression-free survival (PFS) at 6 months by treatment regimen(6 months)
- Median progression-free survival (PFS) at 12 months by treatment regimen(12 months)
- Median progression-free survival (PFS) at 6 months by disease group(6 months)
- Median progression-free survival (PFS) at 12 months by disease group(12 months)
- Progression-free survival (PFS) rate over time(Up to 3 years)
- Proportion of participants reporting treatment-related adverse events (AEs)(Up to 3 years)
- Percentage of participants with a PSA50 response (prostate cancer patients only)(Up to 3 years)
- Prostate Cancer Patient Progression Free Survival (prostate cancer patients only)(Up to 3 years)
- Median Overall Survival (Endometrial cohort only)(Up to 3 years)
- Overall percent change in tumor size(Up to 3 years)
研究者
Rahul Aggarwal
Principal Investigator
University of California, San Francisco